新治疗策略专门设计作用于多种神经元和生化靶标的候选药物,用来治疗认知损害、运动障碍、抑郁和神经退行性变。为此,开发结合2个或更多下列性质的单分子药物:(1)抑制胆碱酯酶;(2)激活或抑制特异性乙酰胆碱受体或α-肾上腺素能受体亚型;(3)抗炎活性;(4)抑制单胺氧化酶;(5)抑制儿茶酚胺-O-甲基转移酶;(6)产生一氧化氮;(7)神经保护作用;(8)抗凋亡活性;(9)激活线粒体依赖性细胞存活基因和蛋白。 The new treatment strategy specifically designed for a variety of neuronal and biochemical target drug candidates for the treatment of cognitive impairment, dyskinesia, depression and neurodegeneration. To this end, monomolecular drugs that bind to two or more of the following properties have been developed: (1) inhibition of cholinesterase; (2) activation or inhibition of specific acetylcholine receptors or alpha-adrenergic receptor subtypes; (3) ) Anti-inflammatory activity; (4) Inhibition of monoamine oxidase; (5) Inhibition of catecholamine-O-methyltransferase; (6) Production of nitric oxide; (7) Neuroprotective effect; Activates mitochondria-dependent cell survival genes and proteins.